Cellular Biomedicine Group Inc. (CBMG)

14.26
NASDAQ : Health Technology
Prev Close 14.38
Day Low/High 14.07 / 14.65
52 Wk Low/High 12.04 / 25.00
Avg Volume 35.20K
Exchange NASDAQ
Shares Outstanding 19.23M
Market Cap 276.53M
EPS -2.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Cellular Biomedicine Group To Present At International Society For Cell And Gene Therapy Annual Meeting

Cellular Biomedicine Group To Present At International Society For Cell And Gene Therapy Annual Meeting

NEW YORK and SHANGHAI, May 29, 2019 /PRNewswire/ -- Cellular Biomedicine Group, Inc.

Cellular Biomedicine Group To Present At B. Riley FBR Annual Investor Conference

Cellular Biomedicine Group To Present At B. Riley FBR Annual Investor Conference

NEW YORK and SHANGHAI, May 20, 2019 /PRNewswire/ --  Cellular Biomedicine Group, Inc.

Cellular Biomedicine Group Reports First Quarter 2019 Results And Highlights Operational Progress

Cellular Biomedicine Group Reports First Quarter 2019 Results And Highlights Operational Progress

-- Initiated patient recruitment for Phase I trial of anti-BCMA CAR-T therapy targeting relapsed and refractory Multiple Myeloma in China

Cellular Biomedicine Group Announces Results Of 2019 Annual Meeting Of Stockholders

Cellular Biomedicine Group Announces Results Of 2019 Annual Meeting Of Stockholders

NEW YORK and SHANGHAI, April 29, 2019 /PRNewswire/ --  Cellular Biomedicine Group, Inc.

Cellular Biomedicine Group To Report First Quarter 2019 Results And Host Conference Call On May 1, 2019

Cellular Biomedicine Group To Report First Quarter 2019 Results And Host Conference Call On May 1, 2019

NEW YORK and SHANGHAI, April 25, 2019 /PRNewswire/ -- Cellular Biomedicine Group Inc.

Cellular Biomedicine Group Upgraded To NASDAQ Global Select Market

Cellular Biomedicine Group Upgraded To NASDAQ Global Select Market

NEW YORK, April 23, 2019 /PRNewswire/ --  Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) (CBMG or the Company), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases,...

Cellular Biomedicine Group To Participate In Asia Pharma R&D Leaders Summit 2019

Cellular Biomedicine Group To Participate In Asia Pharma R&D Leaders Summit 2019

NEW YORK, April 15, 2019 /PRNewswire/ --  Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) (CBMG or the Company), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases,...

Cellular Biomedicine Group To Present At Annual BioCentury Future Leaders In The Biotech Industry Conference

Cellular Biomedicine Group To Present At Annual BioCentury Future Leaders In The Biotech Industry Conference

NEW YORK, April 5, 2019 /PRNewswire/ --  Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) (CBMG or the Company), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today...

SHAREHOLDER ALERT: Monteverde & Associates PC Launches An Investigation Of The Board Of Directors And Officers

SHAREHOLDER ALERT: Monteverde & Associates PC Launches An Investigation Of The Board Of Directors And Officers

NEW YORK, April 3, 2019 /PRNewswire/ --  Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating the Board of Directors and...

Cellular Biomedicine Group (CBMG) Announces Annual Meeting Of Stockholders

Cellular Biomedicine Group (CBMG) Announces Annual Meeting Of Stockholders

NEW YORK and SHANGHAI, March 28, 2019 /PRNewswire/ -- Cellular Biomedicine Group Inc.

Cellular Biomedicine Group Announces Pricing Of Public Offering Of Common Stock

Cellular Biomedicine Group Announces Pricing Of Public Offering Of Common Stock

NEW YORK, March 21, 2019 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) (CBMG or the Company), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today...

Cellular Biomedicine Group Announces Proposed Follow-on Offering Of Common Stock

Cellular Biomedicine Group Announces Proposed Follow-on Offering Of Common Stock

NEW YORK, March 20, 2019 /PRNewswire/ --  Cellular Biomedicine Group Inc. (Nasdaq: CBMG) (CBMG or the Company), a biopharmaceutical company engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases,...

Cellular Biomedicine Group Shares Cross Below 200 DMA

Cellular Biomedicine Group Shares Cross Below 200 DMA

In trading on Tuesday, shares of Cellular Biomedicine Group Inc crossed below their 200 day moving average of $18.58, changing hands as low as $18.51 per share. Cellular Biomedicine Group Inc shares are currently trading off about 6.1% on the day.

Cellular Biomedicine Group To Present At 8th Annual SVB Leerink Global Healthcare Conference

Cellular Biomedicine Group To Present At 8th Annual SVB Leerink Global Healthcare Conference

SHANGHAI and NEW YORK, Feb. 27, 2019 /PRNewswire/ --  Cellular Biomedicine Group Inc.

Cellular Biomedicine Group Reports Fourth Quarter And Full Year 2018 Financial Results And Recent Operational Progress

Cellular Biomedicine Group Reports Fourth Quarter And Full Year 2018 Financial Results And Recent Operational Progress

- Executed Licensing and Collaboration Agreement with Novartis

Cellular Biomedicine Group (CBMG) Shares Cross Above 200 DMA

Cellular Biomedicine Group (CBMG) Shares Cross Above 200 DMA

In trading on Thursday, shares of Cellular Biomedicine Group Inc crossed above their 200 day moving average of $18.55, changing hands as high as $19.20 per share. Cellular Biomedicine Group Inc shares are currently trading up about 3.1% on the day.

Relative Strength Alert For Cellular Biomedicine Group

Relative Strength Alert For Cellular Biomedicine Group

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

TheStreet Quant Rating: D (Sell)